HELX

Franklin Genomic Advancements ETF · BATS

  • Category Equity
  • Expense Ratio 0.5%
  • Listing Date Feb 27, 2020
  • Volume 1,093.0
  • Market Cap (AUM) $13.14M

Performance

-3.91%

1W

+1.38%

1M

-12.63%

3M

-7.58%

6M

-4.17%

YTD

-1.08%

1Y

Top Holdings

  • Name
    Symbol
    %Assets
  • Medpace Holdings, Inc.MEDP6.95%
  • Vertex Pharmaceuticals IncorporatedVRTX5.51%
  • Regeneron Pharmaceuticals, Inc.REGN5.14%
  • Danaher CorporationDHR5.11%
  • Thermo Fisher Scientific Inc.TMO4.75%
  • Eli Lilly and CompanyLLY4.69%
  • Krystal Biotech, Inc.KRYS4.36%
  • Natera, Inc.NTRA3.49%
  • Astrazeneca PLC Sponsored ADRAZN2.74%
  • SAMSUNG BIOLOGICS Co., Ltd.2079402.73%

Technical Analysis of HELX 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 10 indicating strong downward momentum, the Oscillators Score at 43 suggesting a neutral stance, and the Technical Score at 26 reinforcing the overall bearish outlook. This combination signals caution for potential investors, as the prevailing trend ...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.